Valence8 US LP Acquires New Stake in Leap Therapeutics, Inc. (NASDAQ:LPTX)

Valence8 US LP acquired a new position in shares of Leap Therapeutics, Inc. (NASDAQ:LPTX) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 18,511 shares of the company’s stock, valued at approximately $48,000.

Several other hedge funds also recently made changes to their positions in LPTX. Marshall Wace LLP increased its stake in shares of Leap Therapeutics by 268.2% during the second quarter. Marshall Wace LLP now owns 79,758 shares of the company’s stock worth $156,000 after acquiring an additional 58,094 shares during the period. Key Client Fiduciary Advisors LLC boosted its holdings in Leap Therapeutics by 22.2% in the 2nd quarter. Key Client Fiduciary Advisors LLC now owns 284,856 shares of the company’s stock valued at $558,000 after purchasing an additional 51,838 shares in the last quarter. Acadian Asset Management LLC increased its position in Leap Therapeutics by 349.3% during the 1st quarter. Acadian Asset Management LLC now owns 282,413 shares of the company’s stock worth $750,000 after purchasing an additional 219,563 shares during the period. Simplify Asset Management Inc. increased its position in Leap Therapeutics by 67.9% during the 2nd quarter. Simplify Asset Management Inc. now owns 631,269 shares of the company’s stock worth $1,237,000 after purchasing an additional 255,293 shares during the period. Finally, Vanguard Group Inc. lifted its holdings in shares of Leap Therapeutics by 111.7% in the 1st quarter. Vanguard Group Inc. now owns 867,708 shares of the company’s stock valued at $2,308,000 after buying an additional 457,904 shares during the period. Institutional investors and hedge funds own 30.46% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and set a $5.50 price objective on shares of Leap Therapeutics in a report on Friday, November 15th.

Leap Therapeutics Trading Down 1.2 %

LPTX stock opened at $2.56 on Friday. Leap Therapeutics, Inc. has a 52 week low of $1.68 and a 52 week high of $5.00. The company has a market cap of $98.09 million, a P/E ratio of -1.33 and a beta of 0.22. The company’s 50-day moving average price is $2.93 and its 200 day moving average price is $2.57.

Leap Therapeutics Profile

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.